News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NicOx SA (COX.PA) Receives Positive Opinion for European Orphan Drug Designation for Naproxcinod for the Treatment of Duchenne Muscular Dystrophy


9/11/2013 9:35:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Nicox S.A. (NYSE Euronext Paris: COX) today announced that it has received a positive opinion from the European Union Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for naproxcinod, a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory candidate, for the treatment of Duchenne Muscular Dystrophy (DMD). The orphan drug designation allows companies to benefit from a number of incentives, including a 10-year market exclusivity post-approval, scientific advice and fee reductions. Final approval of the opinion on orphan designation is expected from the European Commission in the coming months. Naproxcinod has shown promising preclinical results in models of muscular dystrophy.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
NicOx SA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES